Live
- ‘Anwesha’ offers quality education to ST and SC students
- Congress targeting nationalists to divide country: Dr Laxman
- BJP ‘charge sheet’ accuses BJD govt of rampant corruption
- Delhi court reserves orders on bail petition of Kavitha for May 6
- Konda Vishweshwar Reddy holds rally in Tandur
- Revanth fielding dummy candidates to benefit BJP: KTR
- KTR takes part in road show to boost cadre morale
- YS Jagan Credits YSR for Development in Pulivendula, rubbishes political allegations
- Empowering Patient Education: A Conversation with Naresh Ahuja, CEO of SMS Scientific Products Pvt Ltd
- One dead after car hits lorry at Muthangi Outer Ring Road in Sangareddy
Lupin launches Doxercalciferol drug in US
Drug firm Lupin on Thursday said it has launched its generic Doxercalciferol injection used for treatment of hyperparathyroidism in the US market.
New Delhi: Drug firm Lupin on Thursday said it has launched its generic Doxercalciferol injection used for treatment of hyperparathyroidism in the US market.
The company has launched Doxercalciferol injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vials, after having received an approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a statement.
The product is a generic version of Sanofi Genzyme's Hectorol injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vials, it added.
According to the IQVIA MAT October 2019 data, Doxercalciferol injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vials had an annual sales of around $132 million in the US, Lupin said.
"It is indicated for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis," it added.
